Fortis may be out of F&O if results delayed

The National Stock Exchange of India on Thursday said it will exclude Fortis Healthcare from the derivatives segment if the company fails to submit its financial results for the September and December quarter by March 1, reports Our Bureau.

So far, Fortis Healthcare has failed to submit its quarterly financial results for the September and December quarter, said NSE. Fortis has intimated to exchanges that its board will consider results for the two quarters in meeting on February 28.

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharma launches TEVIMBRA in India